氨甲环酸在出血性剖宫产中的随机安慰剂对照剂量范围药效学辅助试验(TRACES):研究方案
TRACES药效学辅助研究为多中心、随机、双盲、安慰剂对照的氨甲环酸剂量范围试验,针对出血性剖宫产(>800 mL)患者,检测血浆、子宫及尿液氨甲环酸浓度和纤溶酶峰值抑制。计划纳入114例出血性剖宫产和48例非出血性剖宫产患者,来自TRACES临床试验的390例患者。
要点
- 出血性剖宫产(>800 mL)患者随机接受氨甲环酸0.5 g、1 g或安慰剂。
- 采用同步凝血酶-纤溶酶生成试验(STPGA)评估纤溶酶生成抑制。
- 预试验显示氨甲环酸血浆浓度呈剂量依赖性变化。
核心结论
- TRACES药效学辅助试验旨在通过创新检测方法,根据纤溶强度建立出血性剖宫产的治疗策略。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照的氨甲环酸剂量范围研究,同时测量血浆、子宫和尿液氨甲环酸浓度及纤溶酶峰值抑制。
- 计划纳入114例出血性剖宫产(>800 mL)和48例非出血性剖宫产患者,来自TRACES临床试验的390例患者。
主要发现
- 氨甲环酸血浆浓度呈剂量依赖性变化。
- STPGA所有纤溶酶参数的批间变异系数<20%。
- 出血性和非出血性剖宫产组的纤溶酶生成能力个体间离散度高于非妊娠妇女组。
- 各组纤溶酶生成谱随时间变化的模式不同。
关键数值与推荐
- 出血性剖宫产患者盲法接受氨甲环酸0.5 g或1 g或安慰剂。
- 静脉血采样时间点:注射前、注射结束时及注射后30、60、120、360分钟。
- 尿液采样时间点:注射后2小时和6小时。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Evidence increases that a high or a standard dose of tranexamic acid (TA) reduces postpartum bleeding. The TRACES pharmacobiological substudy aims to establish a therapeutic strategy in hemorrhagic (H) Cesarean section (CS) with respect to the intensity of fibrinolysis by using innovative assays. METHOD/DESIGN: The TRACES trial is a multicenter, randomized, double-blind, placebo-controlled, TA dose-ranging study that measures simultaneously plasmatic and uterine and urine TA concentrations and the plasmin peak inhibition tested by a simultaneous thrombin plasmin generation assay described by Van Geffen (novel hemostasis assay [NHA]). Patients undergoing H CS (>800 mL) will receive blindly TA 0.5 g or 1 g or placebo. A non-hemorrhagic (NH) group will be recruited to establish plasmin generation profile. Venous blood will be sampled before, at the end, and then at 30, 60, 120, and 360 min after injection. Uterine bleeding will be sampled after injection. Urine will be sampled 2 h and 6 h after injection. The number of patients entered into the study will be 114 H + 48 NH out of the 390 patients of the TRACES clinical trial. DISCUSSION: To explore the two innovative assays, a preliminary pilot study was conducted. Blood samples were performed repeatedly in patients undergoing either a H (>800 mL) or NH (<800 mL) CS and in non-pregnant women (NP). H patients received TA (0-2 g). Dose-dependent TA plasmatic concentrations were determined by LC-MS/MS quantification. Plasmin generation and its inhibition were tested in vitro and in vivo using the simultaneous thrombin-plasmin generation assay (STPGA). The pilot study included 15 patients in the H group, ten patients in the NH group, and seven patients in the NP group. TA plasmatic concentration showed a dose-dependent variation. STPGA inter-assay variation coefficients were < 20% for all plasmin parameters. Inter-individual dispersion of plasmin generation capacity was higher in H and NH groups than in NP group. Profile evolution over time was different between groups. This preliminary technical validation study allows TRACES pharmacobiological trial to be conducted. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02797119. Registered on 13 June 2016.
引用
- Ducloy-Bouthors AS, Jeanpierre E, Saidi I, et al. TRAnexamic acid in hemorrhagic CESarean section (TRACES) randomized placebo controlled dose-ranging pharmacobiological ancillary trial: study protocol for a randomized controlled trial. Trials. 2018. PMID: 29490690. doi:10.1186/s13063-017-2421-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。